Ardelyx Inc. (NASDAQ:ARDX) is in focus after announcing the publication of its long-term 52-week third phase PHREEDIM study in the American Society of Nephrology Journal, Kideny360.CEO and President Mike Raab said that the study assessed tenapanor monotherapy.
It was the third of the three third phase studies conducted in the evaluation of tenapanor for serum phosphorous control in chronic kidney disease patients on dialysis. Mike said that the data from the study shows tenapanor’s ability to offer considerable phosphorous reduction with extended safety relative to active control.
Most importantly, PHREEDOM study findings plus the AMPLIFY trial data that evaluated tenapanor in conjunction with binders in patients needing aggressive phosphate control support tenapanor’s central role with its unique blocking mechanism in a range of treatment regimens and patients for hyperphosphatemia management in CKD patients in dialysis. Clinical Research Director at Boise Kidney and Hypertension Institute Arnold Silver added that he believes the novel mechanism therapy can be vital in hyperphosphatemia management in CKD patients in dialysis. With progress in the study, ARDX is worth watching.
On Friday, ARDX stock fell 0.63% at $1.44 with more than 14.37 million shares, compared to its average volume of 10.25 million shares. The stock has moved within a range of $1.4200 – 1.5799 after opening the trade at $1.56.